Tenaya Therapeutics (TNYA) on Nov. 8, 2025: FDA Places Clinical Hold on TN‑201 Trial as AHA 2025 Showcases Encouraging MyPEAK‑1 Data
Tenaya Therapeutics presented new interim results from its MyPEAK‑1 Phase 1b/2a trial evaluating TN‑201, an AAV9 gene‑replacement therapy designed to deliver a working MYBPC3 gene to cardiomyocytes for MYBPC3‑associated hypertrophic cardiomyopathy. The late‑breaking presentation in New Orleans highlighted longer‑term follow‑up for the first‑dose cohort and initial readouts at the higher dose, with a simultaneous publication in Cardiovascular Research. GlobeNewswire